Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2016, Article ID 3047329, 12 pages
http://dx.doi.org/10.1155/2016/3047329
Review Article

The Role of Renal Replacement Therapy in the Management of Pharmacologic Poisonings

1Department of Medicine, University of Kentucky College of Medicine, Lexington, KY, USA
2Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA
3Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky College of Medicine, Lexington, KY, USA

Received 6 September 2016; Revised 13 October 2016; Accepted 24 October 2016

Academic Editor: Alessandro Amore

Copyright © 2016 Aibek E. Mirrakhimov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. B. Mowry, D. A. Spyker, L. R. Cantilena Jr., N. McMillan, and M. Ford, “2013 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 31st annual report,” Clinical Toxicology, vol. 52, no. 10, pp. 1032–1283, 2014. View at Publisher · View at Google Scholar
  2. S. H. Rhyee, L. Farrugia, S. L. Campleman, P. M. Wax, and J. Brent, “The toxicology investigators consortium case registry—the 2014 experience,” Journal of Medical Toxicology, vol. 11, no. 4, pp. 388–409, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Orlowski, S. Hou, and J. B. Leikin, “Extracorporeal removal of drugs and toxins,” Clinical Toxicology, 1st Edition, pp. 43–50, 2001.
  4. D. Goldfarb, “Principles and techniques applied to enhance elimination,” in Goldfrank's Toxicologic Emergencies, L. Nelson, N. A. Lewin, M. A. Howland, R. S. Hoffman, L. R. Goldfrank, and N. E. Flomenbaum, Eds., pp. 135–148, McGraw-Hill, 9th edition, 2010. View at Google Scholar
  5. N. S. Kanagasundaram and A. Lewington, “Dialytic therapies for drug overdose and poisoning,” in Comprehensive Clinical Nephrology, chapter 98, pp. 1116–1121, 5th edition, 2014. View at Google Scholar
  6. G. Villa, Z. Ricci, and C. Ronco, “Renal Replacement Therapy,” Critical Care Clinics, vol. 31, no. 4, pp. 839–848, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. L. G. Forni and P. J. Hilton, “Continuous hemofiltration in the treatment of acute renal failure,” New England Journal of Medicine, vol. 336, no. 18, pp. 1303–1309, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. Z. Kim and D. S. Goldfarb, “Continuous renal replacement therapy does not have a clear role in the treatment of poisoning,” Nephron—Clinical Practice, vol. 115, pp. c1–c6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. W. Kerns II, C. Tomaszewski, K. McMartin et al., “Formate kinetics in methanol poisoning,” Journal of Toxicology—Clinical Toxicology, vol. 40, no. 2, pp. 137–143, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. J. E. Davis, “Are one or two dangerous? Methyl salicylate exposure in toddlers,” Journal of Emergency Medicine, vol. 32, no. 1, pp. 63–69, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Y. Wick, “Aspirin: a history, a love story,” Consultant Pharmacist, vol. 27, no. 5, pp. 322–329, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. D. N. Juurlink, S. Gosselin, J. T. Kielstein et al., “Extracorporeal treatment for salicylate poisoning: systematic review and recommendations from the EXTRIP workgroup,” Annals of Emergency Medicine, vol. 66, no. 2, pp. 165–181, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. M. E. Ward, M. N. Musa, and L. Bailey, “Clinical pharmacokinetics of lithium,” Journal of Clinical Pharmacology, vol. 34, no. 4, pp. 280–285, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. R. F. McKnight, M. Adida, K. Budge, S. Stockton, G. M. Goodwin, and J. R. Geddes, “Lithium toxicity profile: a systematic review and meta-analysis,” The Lancet, vol. 379, no. 9817, pp. 721–728, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. M. M. Sood and R. Richardson, “Negative anion gap and elevated osmolar gap due to lithium overdose,” Canadian Medical Association Journal, vol. 176, no. 7, pp. 921–923, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Eyer, R. Pfab, N. Felgenhauer et al., “Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures,” Journal of Clinical Psychopharmacology, vol. 26, no. 3, pp. 325–330, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. R. M. Nanau and M. G. Neuman, “Adverse drug reactions induced by valproic acid,” Clinical Biochemistry, vol. 46, no. 15, pp. 1323–1338, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. M. F. B. Silva, C. C. P. Aires, P. B. M. Luis et al., “Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review,” Journal of Inherited Metabolic Disease, vol. 31, no. 2, pp. 205–216, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Ghannoum, M. Laliberté, T. D. Nolin et al., “Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup,” Clinical Toxicology, vol. 53, no. 5, pp. 454–465, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. K. T. Kopec and M. J. Kowalski, “Metformin-Associated Lactic Acidosis (MALA): case files of the Einstein Medical Center medical toxicology fellowship,” Journal of Medical Toxicology, vol. 9, no. 1, pp. 61–66, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. A. J. Scheen, “Clinical pharmacokinetics of metformin,” Clinical Pharmacokinetics, vol. 30, no. 5, pp. 359–371, 1996. View at Publisher · View at Google Scholar · View at Scopus
  22. S. I. Rifkin, C. McFarren, R. Juvvadi, and S. S. Weinstein, “Prolonged hemodialysis for severe metformin intoxication,” Renal Failure, vol. 33, no. 4, pp. 459–461, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. G. J. Hankey and J. W. Eikelboom, “Dabigatran etexilate: a new oral thrombin inhibitor,” Circulation, vol. 123, no. 13, pp. 1436–1450, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Alikhan, R. Rayment, D. Keeling et al., “The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran,” Emergency Medicine Journal, vol. 31, no. 2, pp. 163–168, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. C. V. Pollack Jr., P. A. Reilly, J. Eikelboom et al., “Idarucizumab for dabigatran reversal,” New England Journal of Medicine, vol. 373, no. 6, pp. 511–520, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Chai-Adisaksopha, C. Hillis, W. Lim, K. Boonyawat, K. Moffat, and M. Crowther, “Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review,” Journal of Thrombosis and Haemostasis, vol. 13, no. 10, pp. 1790–1798, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Bouchard, M. Ghannoum, A. Bernier-Jean et al., “Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran,” Clinical Toxicology, vol. 53, no. 3, pp. 156–163, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. J. L. Harder, M. Heung, A. M. Vilay, B. A. Mueller, and J. H. Segal, “Carbamazepine and the active epoxide metabolite are effectively cleared by hemodialysis followed by continuous venovenous hemodialysis in an acute overdose,” Hemodialysis International, vol. 15, no. 3, pp. 412–415, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Ozhasenekler, S. Gökhan, C. Güloğlu, M. Orak, and M. Ustündağ, “Benefit of hemodialysis in carbamazepine intoxications with neurological complications,” European Review for Medical and Pharmacological Sciences, vol. 16, supplement 1, pp. 43–47, 2012. View at Google Scholar
  30. A. Azak, G. Koçak, B. Huddam, and M. Duranay, “Is conventional hemodialysis enough to manage carbamazepine intoxication?” Blood Purification, vol. 33, no. 4, pp. 225–226, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. B. F. Palmer, “Effectiveness of hemodialysis the extracorporeal therapy of phenobarbital overdose,” American Journal of Kidney Diseases, vol. 36, no. 3, pp. 640–643, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. F. Jacobs and F. G. Brivet, “Conventional haemodialysis significantly lowers toxic levels of phenobarbital,” Nephrology Dialysis Transplantation, vol. 19, no. 6, pp. 1663–1664, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Hoyland, M. Hoy, R. Austin, and M. Wildman, “Successful use of haemodialysis to treat phenobarbital overdose,” BMJ Case Reports, vol. 2013, 2013. View at Google Scholar · View at Scopus
  34. M. Ghannoum, S. Troyanov, P. Ayoub, V. Lavergne, and T. Hewlett, “Successful hemodialysis in a phenytoin overdose: case report and review of the literature,” Clinical Nephrology, vol. 74, no. 1, pp. 59–64, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. V.-C. Wu, S.-L. Lin, S.-M. Lin, and C.-C. Fang, “Treatment of baclofen overdose by haemodialysis: A Pharmacokinetic Study,” Nephrology Dialysis Transplantation, vol. 20, no. 2, pp. 441–443, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Brvar, M. Vrtovec, D. Kovač, G. Kozelj, T. Pezdir, and M. Bunc, “Haemodialysis clearance of baclofen,” European Journal of Clinical Pharmacology, vol. 63, no. 12, pp. 1143–1146, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. M.-J. Hsieh, S.-C. Chen, T.-I. Weng, C.-C. Fang, and T.-J. Tsai, “Treating baclofen overdose by hemodialysis,” American Journal of Emergency Medicine, vol. 30, no. 8, pp. 1654.e5–1654.e7, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. R. T. Sperling, D. S. Pinto, K. K. L. Ho, and J. P. Carrozza Jr., “Platelet glycoprotein IIb/IIIa inhibition with eptifibatide: prolongation of inhibition of aggregation in acute renal failure and reversal with hemodialysis,” Catheterization and Cardiovascular Interventions, vol. 59, no. 4, pp. 459–462, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. C. P. Snook, K. Sigvaldason, and J. Kristinsson, “Severe atenolol and diltiazem overdose,” Journal of Toxicology—Clinical Toxicology, vol. 38, no. 6, pp. 661–665, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. S.-H. S. Huang, R. G. Tirona, C. Ross, and R. S. Suri, “Case report: atenolol overdose successfully treated with hemodialysis,” Hemodialysis International, vol. 17, no. 4, pp. 652–655, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. T. W. Belay and A. R. Nusair, “Apparent lisinopril overdose requiring hemodialysis,” American Journal of Health-System Pharmacy, vol. 70, no. 14, pp. 1226–1229, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. A. S. Shalkham, B. M. Kirrane, R. S. Hoffman, D. S. Goldfarb, and L. S. Nelson, “The availability and use of charcoal hemoperfusion in the treatment of poisoned patients,” American Journal of Kidney Diseases, vol. 48, no. 2, pp. 239–241, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. J. A. Kraut, “Diagnosis of toxic alcohols: limitations of present methods,” Clinical Toxicology, vol. 53, no. 7, pp. 589–595, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. R. J. Slaughter, R. W. Mason, D. M. G. Beasley, J. A. Vale, and L. J. Schep, “Isopropanol poisoning,” Clinical Toxicology, vol. 52, no. 5, pp. 470–478, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. L. J. Schep, R. J. Slaughter, W. A. Temple, and D. M. G. Beasley, “Diethylene glycol poisoning,” Clinical Toxicology, vol. 47, no. 6, pp. 525–535, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. H. K. Tan, “Molecular adsorbent recirculating system (MARS),” Annals of the Academy of Medicine Singapore, vol. 33, no. 3, pp. 329–335, 2004. View at Google Scholar · View at Scopus
  47. D. G. Barceloux, E. P. Krenzelok, K. Olson, W. Watson, and H. Miller, “American academy of clinical toxicology practice guidelines on the treatment of ethylene glycol poisoning,” Journal of Toxicology—Clinical Toxicology, vol. 37, no. 5, p. 537, 1999. View at Publisher · View at Google Scholar · View at Scopus
  48. D. G. Barceloux, G. R. Bond, E. P. Krenzelok, H. Cooper, and J. A. Vale, “American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning,” Journal of Toxicology—Clinical Toxicology, vol. 40, no. 4, pp. 415–446, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Pizon and D. Brooks, “Hyperosmolality: another indication for hemodialysis following acute ethylene glycol poisoning,” Clinical Toxicology, vol. 44, no. 2, pp. 181–183, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. W. H. Porter, P. W. Rutter, B. A. Bush, A. A. Pappas, and J. E. Dunnington, “Ethylene glycol toxicity: the role of serum glycolic acid in hemodialysis,” Journal of Toxicology—Clinical Toxicology, vol. 39, no. 6, pp. 607–615, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. M. A. Darracq, L. L. Rentmeester, R. F. Clark, C. A. Tomaszewski, A. B. Schneir, and F. L. Cantrell, “Cost of hemodialysis versus fomepizole-only for treatment of ethylene glycol intoxication,” Clinical Toxicology, vol. 51, no. 3, p. 188, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Herres, D. Ryan, and M. Salzman, “Delayed salicylate toxicity with undetectable initial levels after large-dose aspirin ingestion,” American Journal of Emergency Medicine, vol. 27, no. 9, pp. 1173–e1, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Wong, K. Mac, A. Aneman, J. Wong, and B. S. Chan, “Modern Intermittent Haemodialysis (IHD) is an effective method of removing salicylate in chronic topical salicylate toxicity,” Journal of Medical Toxicology, vol. 12, no. 1, pp. 130–133, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. J. B. Hill, “Salicylate intoxication,” New England Journal of Medicine, vol. 288, no. 21, pp. 1110–1113, 1973. View at Publisher · View at Google Scholar · View at Scopus
  55. J. K. Glisson, T. S. Vesa, and M. R. Bowling, “Current management of salicylate-induced pulmonary edema,” Southern Medical Journal, vol. 104, no. 3, pp. 225–232, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. A. D. Strobusch and J. W. Jefferson, “The checkered history of lithium in medicine,” Pharmacy in History, vol. 22, no. 2, pp. 72–76, 1980. View at Google Scholar · View at Scopus
  57. R. Oruch, M. A. Elderbi, H. A. Khattab, I. F. Pryme, and A. Lund, “Lithium: a review of pharmacology, clinical uses, and toxicity,” European Journal of Pharmacology, vol. 740, pp. 464–473, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. M. D. Sztajnkrycer, “Valproic acid toxicity: overview and management,” Journal of Toxicology—Clinical Toxicology, vol. 40, no. 6, pp. 789–801, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Hajjar, M. A. Habra, and A. Naing, “Metformin: an old drug with new potential,” Expert Opinion on Investigational Drugs, vol. 22, no. 12, pp. 1511–1517, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Okada, S. Teramoto, and R. Matsuoka, “Recovery from theophylline toxicity by continuous hemodialysis with filtration,” Annals of Internal Medicine, vol. 133, no. 11, p. 922, 2000. View at Google Scholar · View at Scopus
  61. J. Kneser, P. Wehmeier, R. Lichtinghagen, M. M. Hoeper, and J. T. Kielstein, “Successful treatment of life threatening theophylline intoxication in a pregnant patient by hemodialysis,” Clinical Nephrology, vol. 80, no. 1, pp. 72–74, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. L.-Y. Mani, S. Kissling, D. Viceic et al., “Intermittent hemodialysis treatment in cefepime-induced neurotoxicity: case report, pharmacokinetic modeling, and review of the literature,” Hemodialysis International, vol. 19, no. 2, pp. 333–343, 2015. View at Publisher · View at Google Scholar · View at Scopus
  63. A. M. Burda, C. B. Fischbein, T. Howe, T. R. Sigg, and M. A. Wahl, “Hemodialysis clearance of metronidazole following overdose,” Annals of Pharmacotherapy, vol. 39, no. 7-8, p. 1366, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. G. Thunga, K. G. Sam, D. Patel et al., “Effectiveness of hemodialysis in acute dapsone overdose—a case report,” American Journal of Emergency Medicine, vol. 26, no. 9, pp. 1070.e1–1070.e4, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. K. Skinner, A. Saiao, A. Mostafa et al., “Isoniazid poisoning: pharmacokinetics and effect of hemodialysis in a massive ingestion,” Hemodialysis International, vol. 19, no. 4, pp. E37–E40, 2015. View at Publisher · View at Google Scholar · View at Scopus
  66. M. L. A. Sivilotti, D. N. Juurlink, J. S. Garland et al., “Antidote removal during haemodialysis for massive acetaminophen overdose,” Clinical Toxicology, vol. 51, no. 9, pp. 855–863, 2013. View at Publisher · View at Google Scholar · View at Scopus